Clinical Research Liaison
TempusFull Time
Entry Level & New Grad, Junior (1 to 2 years)
Candidates must possess a Bachelor's degree and at least 5 years of hands-on clinical trial experience, preferably in a pharmaceutical or biotech setting, with a combination of CRO and sponsor-side experience being advantageous. Demonstrated experience in conducting first-in-human and complex autoimmune clinical trials, including setup, monitoring, and close-out, is essential. A strong working knowledge of ICH/GCP regulations and proficiency with electronic systems like eTMF, CTMS, and EDC are required. The ideal candidate will exhibit strong critical thinking, a sense of urgency, proactive problem-solving skills, and excellent interpersonal, written, and verbal communication abilities, along with proficiency in MS Office and comfort with technology. Ability to work independently and collaboratively in a team environment is also necessary.
The Clinical Trial Manager will oversee the strategic implementation and execution of clinical trials from start-up to close-out, managing CROs, study vendors, and clinical trial sites. This role involves ensuring trials are completed on time, within budget, and in accordance with regulatory requirements, GCP guidelines, and internal SOPs. Key duties include preparing and maintaining study files, organizing meetings, coordinating clinical trial equipment and supplies, ensuring team compliance with training, performing TMF reviews, supporting sites for audits, assisting with budget management, tracking subject and site activity, identifying and escalating issues, and contributing to study setup activities such as protocol development and regulatory submissions. The manager will also collaborate with CROs for TMF document collection, coordinate with regulatory affairs, support study close-out activities, and communicate effectively with study team members, while participating in process improvement initiatives.
Develops therapies for autoimmune diseases
Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.